drug
Toujeo LA
Marketedupdated 3mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval24 co-mentions · 12 sources
- drugSOLIQUA 100/3324 co-mentions · 12 sources
- druginsulin glargine LA12 co-mentions · 12 sources
- drug(insulin glargine + lixisenatide)12 co-mentions · 12 sources
- drugAbasaglar12 co-mentions · 12 sources
- druginsulin12 co-mentions · 12 sources
- company$SNYSanofi12 co-mentions · 12 sources
- company$SNYNFSanofi12 co-mentions · 12 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.
indications
investigational
Type 2 Diabetes
all catalysts(12)
approval · 12
Nov 21, 2016
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Aug 29, 2017
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Sep 28, 2017
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Feb 27, 2019
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Nov 15, 2019
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Nov 15, 2019
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Jul 28, 2021
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Jun 10, 2022
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Sep 28, 2023
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Nov 1, 2024
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
May 28, 2025
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Mar 12, 2026
approval
SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approval
Toujeo LA
→
Trials studying Toujeo LA
- phase4A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
- phase3A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
- phase3A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- phase3A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
- phase3A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- phase3A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
- phase4iGlarLixi CGM Study in Chinese T2D Individuals After OADs
- phase3A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
News(4)
- STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and moreSeven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 eachstat · 7d ago
- STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and moreIn a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugsstat · 27d ago
- A new, separate outbreak of the diarrhea-causing parasiteA win for peptide proponents, autism advisory committees clash, and more health news from Morning Roundsstat · 27d ago
- STAT+: Popular insulin product enters shortage as other pens leave marketThe Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.stat · 28d ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that